Abstract library

6 results for "Tatangelo".
#860 Expression and Prognostic Role of CXCR4/CXCL12/CXCR7 and mTOR Pathways in Neuroendocrine Tumors (NETs)
Introduction: The chemokine receptor CXCR4 interacts with the ligand CXCL12 to exert proliferative and chemotactic effects. CXCR4 activates mTOR through phosphorylation of its two effectors downstream:4EBP1and S6K
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Doctor Luisa Circelli
#963 From E.L.I.O.S. (Educational Learning Investigational Observational Study) an Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1000 E.L.I.O.S. (Educational Learning Investigational Observational Study): An Initial Update on Neuroendocrine Tumors (NETs) in the Southern Italy
Introduction: Elios is an Educational Learning Investigational Observational Study.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: MD Salvatore Tafuto
#1109 Expression and Role of the CXCR4/CXCL12/CXCR7 Axis and Crosstalk with the mTOR Pathway in Neuroendocrine Tumors (NETs)
Introduction: Chemokine receptor CXCR4 has been shown to signal on mTOR pathway in gastric and renal cancer. CXCR4 interacts with the chemokine CXCL12 to exert proliferative and chemotactic effects.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: student Concetta Sciammarella
#2047 IMMUNeOCT Study: The Role of Octreotide LAR in Modulating the Immune Response in Patient with Neuroendocrine Tumors. EudraCT Number 2017-001613-83
Introduction: SSAs are used in the treatment of G1/G2 Neuroendocrine Neoplasms (NEN) in order to control symptoms and induce tumor shrinkage with an excellent tolerability profile. The role of immune response is crucial in defining the clinical response to treatment through the active stimulation of effector cells (T and NK cells) but also through the inhibition of tumor-induced immune suppression. The immune regulatory cells CD4-CD25-expressing Tregs and myeloid cellsMDSC can contribute to disease progression through various mechanisms.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Salvatore Tafuto
#2801 IMMUNeOCT: OCT LAR in the Induction of Immunologic Response in Patients with Neuroendocrine Neoplasms (NENs): A Perspective Observational and Translational Study (EudraCT2017-001613-83)
Introduction: The possible impact of octreotide (OCT) Long-Acting Release (LAR) on the immune system regulation is largely unexplored.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Biomarkers
Presenting Author: MD Alessandro Ottaiano